加载中
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
常规交易时段
US$1.605
−US$0.135 · -7.76%
盘中时间采用ET。市场数据可能有所延迟。
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
日内区间
当前US$1.605
52周区间
当前US$1.605
盘中时间采用ET。市场数据可能有所延迟。
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
日内区间
当前US$1.605
52周区间
当前US$1.605
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7556.42万 USD | 1012万 USD | 169.8万 USD | 619.4万 USD | 150.7万 USD |
| 销货成本 | 9659.42万 USD | 1.41亿 USD | — | — | — |
| 毛利 | −2103万 USD | −1.31亿 USD | 169.8万 USD | 619.4万 USD | 150.7万 USD |
| 研究与开发 | 1.29亿 USD | 1.58亿 USD | 1.3亿 USD | 1.17亿 USD | 1.11亿 USD |
| 销售、一般及管理费用 | 1.32亿 USD | — | 4674.5万 USD | 3189.9万 USD | 3186.5万 USD |
| 营业费用 | 2.6亿 USD | 1.11亿 USD | 1.81亿 USD | 1.49亿 USD | 1.42亿 USD |
| 利息收入 | 1902.44万 USD | 3235.5万 USD | 1350.5万 USD | 170.8万 USD | 26.2万 USD |
| 利息支出 | 3675.57万 USD | 929.4万 USD | 4506.7万 USD | 890.5万 USD | 110.5万 USD |
| 折旧和摊销 | 981.4万 USD | 771.6万 USD | 656.5万 USD | 742.2万 USD | 845.8万 USD |
| 营业利润 | −2.81亿 USD | −2.41亿 USD | −1.8亿 USD | −1.43亿 USD | −1.4亿 USD |
| 净利润 | −2.88亿 USD | −2.21亿 USD | −2.08亿 USD | −1.49亿 USD | −1.42亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.87
上涨空间 452.65%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB232.48万0.02%108.2亿 USD0.44%US$200.51-1.84%
Tema Oncology ETFCANC48.09万0.24%2.03亿 USD0.99%US$39.34-3.05%
State Street SPDR S&P International Small Cap ETFGWX17.84万0.02%9.15亿 USD0.40%US$45.38+0.27%
Invesco NASDAQ Future Gen 200 ETFQQQS9.18万0.40%2275.83万 USD0.20%US$40.7101-1.70%
ActivePassive International Equity ETFAPIE5.52万—11.36亿 USD0.45%US$38.535+0.35%
Invesco Nasdaq Biotechnology ETFIBBQ2.7万0.02%1.12亿 USD0.19%US$33.55-2.04%
ProShares Ultra Nasdaq BiotechnologyBIB1.34万0.01%9138.97万 USD1.19%US$104.14-4.28%iShares Biotechnology ETFIBBTema Oncology ETFCANCState Street SPDR S&P International Small Cap ETFGWXInvesco NASDAQ Future Gen 200 ETFQQQSActivePassive International Equity ETFAPIEInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
